ULURU Inc. Announces Expansion Of The Altrazeal® International Marketing Network

Jul 08, 2013, 09:39 ET from ULURU Inc.

ADDISON, Texas, July 8, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR) today announced the expansion of the Altrazeal® international marketing network to include South Africa, Czech, Slovakia and Portugal.

Marketing and distribution agreements have been signed with companies to exclusively distribute Altrazeal® in these territories. Production of the initial product orders has commenced and we are forecasting that these orders will be shipped in the third quarter of 2013.

Commenting on the expansion of the Altrazeal® international marketing network, Helmut Kerschbaumer, Managing Director of Altrazeal Trading Ltd., stated "This expansion represents the first phase in appointing marketing and distribution partners throughout the territory. Now that we have a wealth of positive clinical data generated internationally and the clear demonstration of the economic benefits of Altrazeal® the interest by potential partners has exceeded our expectations. With the increased exposure of Altrazeal® at international wound care conferences, we have received inquiries from countries throughout the territory requesting the marketing rights for Altrazeal®. We believe we are on schedule to have Altrazeal® marketed in a total of 15-20 countries by year end."

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com.  For further information about Altrazeal®, please visit our website at www.altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the response of potential partners related to the benefits of Altrazeal®, and the expectation of marketing Altrazeal® in new territories.  When used in this press release, the words "believe," "expect" and "anticipate" and similar expressions may be indicative of forward-looking statements.  These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145